Yuanbao (YB) Q2 2026 Earnings Call Transcript

During Yuanbao Inc.'s Q2 2026 Earnings Conference Call, Chairman and CEO Rui Fang highlighted the company's continued growth and strategic initiatives. Q2 2026 saw a 30.1% year-over-year increase in total revenue, reaching RMB 1.39 billion. Net income also improved, rising 35.6% to RMB 413.2 million, with a net income margin of 29.7%. As of the quarter's end, Yuanbao held cash reserves of RMB 5.16 billion.

Fang emphasized the company's investments in AI technology and product innovation in collaboration with insurance carriers, which had expanded their model matrix to over 5,100 models capable of analyzing more than 5,900 labels. This growth in data and modeling capabilities drove improvements in service efficiency and user experience. Additionally, Yuanbao continued to repurchase shares, having acquired approximately 114,000 ADSs for about USD 1.6 million as of August 31, 2026.

The report on the work of the government and the National Health Plan for the 15th Five-Year Plan period highlighted the importance of commercial health insurance and innovative drugs. In response, Yuanbao strengthened its collaboration with insurance carriers and accelerated product iteration, focusing on affordability, comprehensive coverage, and quality service.

The company's Super Medical Insurance series underwent a comprehensive upgrade in June, enhancing coverage across the full treatment journey, including access to special needs medical resources, advanced drugs, medical devices, and inpatient rehabilitation.